Jenburkt Pharmaceuticals Ltd
BSE:524731
Jenburkt Pharmaceuticals Ltd
Cash & Cash Equivalents
Jenburkt Pharmaceuticals Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Jenburkt Pharmaceuticals Ltd
BSE:524731
|
Cash & Cash Equivalents
â‚ą776.9m
|
CAGR 3-Years
17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
13%
|
||
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash & Cash Equivalents
â‚ą11.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
||
Cipla Ltd
NSE:CIPLA
|
Cash & Cash Equivalents
â‚ą9.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
16%
|
||
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash & Cash Equivalents
â‚ą90.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
||
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash & Cash Equivalents
â‚ą11.5B
|
CAGR 3-Years
49%
|
CAGR 5-Years
14%
|
CAGR 10-Years
7%
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Cash & Cash Equivalents
â‚ą1.2B
|
CAGR 3-Years
-45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Jenburkt Pharmaceuticals Ltd
Glance View
Jenburkt Pharmaceuticals Ltd. engages in the manufacture and marketing of pharmaceutical formulations and healthcare products. The company is headquartered in Mumbai, Maharashtra and currently employs 730 full-time employees. The firm offers pharmaceutical products for various therapeutic areas, analgesic and antipyretics anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants/antacids, aphrodisiac, consumer division, cough and cold, muscle relaxants neuropathic pain, nutraceuticals and pain management. The firm's product brands include Allerzine tablets, Cartisafe forte MSM tablets, Eberjen Cream and SOL, ECOPROT powder, Frendacid suspension, Fundu tablets, Glajen-E capsules, GLUCOTROL tablets, Jenflam tablets, Lutriben cream, Ornel tablets, Pantazole tablets and others. The firm's manufacturing plant is located in Sihor-Gujarat. The firm's products are exported to approximately 13 countries globally.
See Also
What is Jenburkt Pharmaceuticals Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
776.9m
INR
Based on the financial report for Sep 30, 2024, Jenburkt Pharmaceuticals Ltd's Cash & Cash Equivalents amounts to 776.9m INR.
What is Jenburkt Pharmaceuticals Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
13%
Over the last year, the Cash & Cash Equivalents growth was 39%. The average annual Cash & Cash Equivalents growth rates for Jenburkt Pharmaceuticals Ltd have been 17% over the past three years , 8% over the past five years , and 13% over the past ten years .